This work further supports the concept that aiding SOD1 maturation is a potential therapeutic approach for SOD1-associated ALS and that polytherapy may be more effective than a monotherapy, particularly in regards to CuATSM, which has reached clinical trials. Here, SOD1 is linked to amyotrophic lateral sclerosis.